Buy Caduet (Amlodipine Besylate, Atorvastatin Calcium) cardiovascular medication
Cheap qualitative Amlodipine with Atorvastatin 2.5/10 mg, 5/10 mg tablets online
HOW AND WHERE TO BUY CADUET (AMLODIPINE, ATORVASTATIN) 2.5/10 MG, 5/10 MG TABLETS OR CAPSULES ONLINE:
GENERIC DRUGS SHOP
from $1.00 per pill
15% discount coupon: qRr3ZyvhPv
from $1.38 per pill
5% discount coupon: MSD5
from $1.86 per pill
10% discount coupon: hf-5478
CADUET (AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM) TABLETS: WARNINGS
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with the atorvastatin component of Caduet and with other statins. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.
The atorvastatin component of Caduet, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values > 10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.
Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. Caduet therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
The risk of myopathy during treatment with statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, clarithromycin, erythromycin, combination of ritonavir plus saquinavir or lopinavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with Caduet and fibric acid derivatives, clarithromycin, erythromycin, a combination of ritonavir plus saquinavir or lopinavir plus ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.
In patients taking Caduet, therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, major surgery, hypotension, trauma, severe metabolic, endocrine and electrolyte disorders, uncontrolled seizures).
Statins, like the atorvastatin component of Caduet and like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations ( > 3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.
In clinical trials in patients taking the atorvastatin component of Caduet (Amlodipine, Atorvastatin), the following has been observed. One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients, with persistent LFT elevations continued treatment with a reduced dose of atorvastatin.
It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Liver enzyme changes generally occur in the first 3 months of treatment with the atorvastatin component of Caduet. Patients who develop increased transaminase levels should be monitored until the abnormalities resolve. Should an increase in ALT or AST of > 3 times ULN persist, reduction of dose or withdrawal of Caduet is recommended.
Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of Caduet (Amlodipine, Atorvastatin) tablets.
Increased Angina and/or Myocardial Infarction
Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease.
Purchase Caduet (Amlodipine, Atorvastatin) Online
Caduet prescribing information
Copyright © 2016-2019 Amlodipine-Atorvastatin.2ordermeds.org, a division of Pharma-Doctor.com pharmaceutical network.
Home Page |
Cookies Policy |
Terms of Service |